Ceraxon (Cyticolin) 1000 mg / 4 ml amp 5 pcs

4 ml solution contains:
active substance: sodium citicoline (equivalent to 1000 mg of citicoline)      
excipients: 1M hydrochloric acid or 1M sodium hydroxide - up to pH 6.7–7.1; water for injection - up to 4 ml

Ceraxon is a nootropic drug.

Citicoline, being a precursor to key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it helps repair damaged cell membranes, inhibits the action of phospholipases, preventing the formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis.

In the acute period of a stroke, citicoline reduces the amount of damage to brain tissue, improves cholinergic transmission.

In traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, citicoline helps to reduce the duration of the recovery period.

In chronic cerebral hypoxia, citicoline is effective in the treatment of cognitive impairment, such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.

Ceraxon ^{® is}  effective in the treatment of sensitive and motor neurological disorders of degenerative and vascular etiology.

• acute period of ischemic stroke (as part of complex therapy);
• recovery period of ischemic and hemorrhagic strokes;
• TBI, acute (as part of complex therapy) and recovery period;
• cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

There are no sufficient data on the use of citicoline in pregnant women. Although animal studies have not revealed a negative effect, during pregnancy, the drug Cerakson ^{® is} prescribed only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

When prescribing Ceraxon ^® during lactation, women should stop breastfeeding, since there is no data on the release of citicoline with breast milk.

• hypersensitivity to any of the components of the drug;
• severe vagotonia (the predominance of the tone of the parasympathetic part of the autonomic nervous system);
• rare hereditary diseases associated with fructose intolerance;
• children under 18 years (due to lack of sufficient clinical data).

Very rare (less than 1/10000) (including individual cases): allergic reactions (rash, skin itching, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, swelling, shortness of breath, insomnia, agitation, loss of appetite, numbness in paralyzed limbs, change in the activity of liver enzymes. In some cases, Ceraxon ^® can stimulate the parasympathetic system, as well as cause a short-term change in blood pressure.

If any of the side effects indicated in the instructions are exacerbated, or any other side effects not listed in the instructions have been noticed, you should inform your doctor.

Citicoline enhances the effects of levodopa.

Ceraxon ^® should not be prescribed concurrently with medicines containing meclofenoxate.

Intravenously, the drug is administered as a slow injection (within 3-5 minutes, depending on the prescribed dose) or drip infusion (40-60 drops per minute). An intravenous route of administration is preferable to an intramuscular route. With intramuscular administration, repeated administration of the drug in the same place should be avoided.

Acute period of ischemic stroke and traumatic brain injury: the recommended dose is 1000 mg every 12 hours from the first day after diagnosis; the duration of treatment is at least 6 weeks. 3-5 days after the start of treatment (if swallowing function is not impaired), the transition to oral forms of the drug Ceraxon ^® is possible .

The recovery period of ischemic and hemorrhagic strokes, the recovery period for traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg / day. (5-10 ml 1-2 times / day.). The dose and duration of treatment depend on the severity of the symptoms of the disease.

Acute period of ischemic stroke and traumatic brain injury: the recommended dose is 1000 mg every 12 hours from the first day after diagnosis; the duration of treatment is at least 6 weeks. 3-5 days after the start of treatment (if swallowing function is not impaired), the transition to oral forms of the drug Ceraxon ^® is possible .

The recovery period of ischemic and hemorrhagic strokes, the recovery period for traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg / day. (5-10 ml 1-2 times / day.). The dose and duration of treatment depend on the severity of the symptoms of the disease.

Given the low toxicity of the drug, cases of overdose are not described.

During the treatment period, care should be taken when performing potentially hazardous activities that require special attention and quick reactions (driving a car and other vehicles, working with moving mechanisms, the work of a dispatcher and operator, etc.).

Solution for oral administration (optional). In the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative. Upon further storage under the recommended conditions, the crystals dissolve within a few months. The presence of crystals does not affect the quality of the drug.

Injection.